News & Publications

News & Publications

News & Publications

05.13.22 - news

HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022

04.28.22 - news

HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer

03.03.22 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment

02.24.22 - news

HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

12.23.21 - publication

GCN2 kinase activation by ATP-competitive kinase inhibitors

12.14.21 - news

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Patients with Metastatic Breast Cancer

12.09.21 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021

12.07.21 - news

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium

10.26.21 - publication

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort

10.26.21 - news

HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19

09.30.21 - news

HiberCell Appoints Jonathan Lanfear as COO

09.24.21 - publication

Targeting the Integrated Stress Response in Cancer Therapy

09.08.21 - news

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

08.16.21 - news

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

07.30.21 - publication

The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer

07.30.21 - publication

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

06.29.21 - news

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer

06.10.21 - news

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

05.19.21 - news

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital

04.28.21 - publication

Quantum processor-inspired machine learning in the biomedical sciences

01.21.21 - news

HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.

01.17.21 - publication

Activation of the Integrated Stress Response overcomes multidrug resistance in FBXW7-deficient cells

01.13.21 - news

HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization

12.02.20 - news

HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

11.05.20 - publication

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

07.07.20 - news

HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program

04.02.20 - publication

Smooth Muscle Cell Reprogramming in Aortic Aneurysms

04.01.20 - publication

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit

03.13.20 - publication

Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia

02.10.20 - publication

Chronic mTOR activation induces a degradative smooth muscle cell phenotype

12.04.19 - news

Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis

12.01.19 - publication

GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment

12.01.19 - publication

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

11.01.19 - publication

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

11.01.19 - publication

A MYC-GCN2-eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer

11.01.19 - publication

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects

11.01.19 - publication

Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab

08.06.19 - news

HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors

06.13.19 - publication

Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium

05.01.19 - publication

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

02.07.19 - news

STAT – New York biotech debuts, targeting dormant metastatic cancer cells

02.07.19 - news

FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis

02.07.19 - news

Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis

02.07.19 - news

HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics

01.14.19 - publication

Enhancing Retrosynthetic Reaction Prediction with Deep Learning Using Multiscale Reaction Classification

12.18.18 - publication

ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma

10.16.18 - news

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

09.28.18 - news

How dormant cancer persists and reawakens

06.01.18 - publication

Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases

05.01.18 - publication

Development of a stress response therapy targeting aggressive prostate cancer

04.01.18 - publication

Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

04.01.18 - publication

Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

04.01.18 - publication

Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

03.01.18 - publication

The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma

01.01.18 - publication

Role of HIF-1 in Cancer Progression: Novel Insights. A Review

10.10.17 - publication

Recent Insights into the Role of Unfolded Protein Response in ER Stress in Health and Disease

12.13.16 - news

Mechanism of early dissemination and metastasis in Her2+ mammary cancer

08.01.15 - publication

Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy

01.30.15 - news

NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

04.13.14 - publication

Keeping the eIF2 alpha kinase Gcn2 in check

02.24.14 - publication

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

05.13.22 - news

HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022

04.28.22 - news

HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer

03.03.22 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment

02.24.22 - news

HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

12.23.21 - publication

GCN2 kinase activation by ATP-competitive kinase inhibitors

12.14.21 - news

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Patients with Metastatic Breast Cancer

12.09.21 - news

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021

12.07.21 - news

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium

10.26.21 - publication

Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort

10.26.21 - news

HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19

09.30.21 - news

HiberCell Appoints Jonathan Lanfear as COO

09.24.21 - publication

Targeting the Integrated Stress Response in Cancer Therapy

09.08.21 - news

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

08.16.21 - news

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

07.30.21 - publication

The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer

07.30.21 - publication

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

06.29.21 - news

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer

06.10.21 - news

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

05.19.21 - news

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital

04.28.21 - publication

Quantum processor-inspired machine learning in the biomedical sciences

01.21.21 - news

HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.

01.17.21 - publication

Activation of the Integrated Stress Response overcomes multidrug resistance in FBXW7-deficient cells

01.13.21 - news

HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization

12.02.20 - news

HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

11.05.20 - publication

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

07.07.20 - news

HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program

04.02.20 - publication

Smooth Muscle Cell Reprogramming in Aortic Aneurysms

04.01.20 - publication

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit

03.13.20 - publication

Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia

02.10.20 - publication

Chronic mTOR activation induces a degradative smooth muscle cell phenotype

12.04.19 - news

Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis

12.01.19 - publication

GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment

12.01.19 - publication

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

11.01.19 - publication

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

11.01.19 - publication

A MYC-GCN2-eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer

11.01.19 - publication

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects

11.01.19 - publication

Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab

08.06.19 - news

HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors

06.13.19 - publication

Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium

05.01.19 - publication

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

02.07.19 - news

STAT – New York biotech debuts, targeting dormant metastatic cancer cells

02.07.19 - news

FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis

02.07.19 - news

Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis

02.07.19 - news

HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics

01.14.19 - publication

Enhancing Retrosynthetic Reaction Prediction with Deep Learning Using Multiscale Reaction Classification

12.18.18 - publication

ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma

10.16.18 - news

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

09.28.18 - news

How dormant cancer persists and reawakens

06.01.18 - publication

Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases

05.01.18 - publication

Development of a stress response therapy targeting aggressive prostate cancer

04.01.18 - publication

Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

04.01.18 - publication

Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

04.01.18 - publication

Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

03.01.18 - publication

The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma

01.01.18 - publication

Role of HIF-1 in Cancer Progression: Novel Insights. A Review

10.10.17 - publication

Recent Insights into the Role of Unfolded Protein Response in ER Stress in Health and Disease

12.13.16 - news

Mechanism of early dissemination and metastasis in Her2+ mammary cancer

08.01.15 - publication

Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy

01.30.15 - news

NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

04.13.14 - publication

Keeping the eIF2 alpha kinase Gcn2 in check

02.24.14 - publication

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma